Profiling proteomic responses in small intestinal neuroendocrine tumor GOT1 after [177Lu]Lu-DOTATATE therapy

Johan K.E. Spetz, Mikael E. Montelius, Evelin Berger, Julia A.M. Johansson, Nishte Rassol, Maria Ljungberg, Eva B. Forssell-Aronsson · 2026

Read Profiling proteomic responses in small intestinal neuroendocrine tumor GOT1 after [177Lu]Lu-DOTATATE therapy by Johan K.E. Spetz, Mikael E. Montelius, Evelin Berger, Julia A.M. Johansson, Nishte Rassol, Maria Ljungberg, Eva B. Forssell-Aronsson (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13584284.txt.

Description

Johan Spetz and co-authors profile protein changes in a small intestinal neuroendocrine tumor model after radioactive targeted therapy. Their 2026 study uses the GOT1 tumor line and the drug Lu-DOTATATE, an established treatment for such tumors.

The therapy has strong anti-tumor effects in models, yet curative responses in patients stay limited. Mice bearing GOT1 tumors got a non-curative dose of the drug or a saline control. Tumors were collected one day and thirteen days after treatment, to represent early and later responses. Proteomic profiling then mapped which proteins rose or fell. Knowing the molecular response may point to ways to improve the therapy.

Catalog record

CREATORJohan K.E. Spetz, Mikael E. Montelius, Evelin Berger, Julia A.M. Johansson, Nishte Rassol, Maria Ljungberg, Eva B. Forssell-Aronsson
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE44 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13584284

Browse the full library · About the Tower of Babel